GlassScriptPhysician profile
Hannah Mainstain
NPI 1942857917
$7,466.96
in general payments reported to CMS, 2019-2025
39 companies · $75.06 in 2025
The $75.06 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,632 · 2022: $2,008 · 2023: $2,182 · 2024: $1,569 · 2025: $75.06.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,727 · Education: $98.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,727.45 |
| Education | $98.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,611.67 | 2021-2025 | |
| Novo Nordisk INC | $1,064.44 | 2021-2024 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $1,026.18 | 2021-2024 | Mounjaro, Jardiance, Trulicity |
| Astrazeneca Pharmaceuticals LP | $777.01 | 2021-2024 | Farxiga, Breztri, Airsupra |
| Bayer Healthcare Pharmaceuticals INC. | $375.26 | 2022-2024 | |
| Glaxosmithkline, LLC. | $355.50 | 2021-2024 | Shingrix, Trelegy Ellipta, Arexvy |
| Amgen INC. | $265.19 | 2021-2024 | Krystexxa, Otezla, Repatha |
| Pfizer INC. | $260.54 | 2021-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $247.81 | 2021-2025 | Jardiance |
| Sanofi-Aventis U.S. LLC | $183.49 | 2021-2023 | |
| Genzyme Corporation | $151.13 | 2023 | |
| Amarin Pharma, INC. | $143.02 | 2021-2022 | |
| Astellas Pharma US INC | $93.48 | 2021-2024 | |
| Merck Sharp & Dohme LLC | $91.50 | 2021-2024 | Gardasil 9, Capvaxive, Gardasil |
| Corcept Therapeutics | $80.50 | 2024 | Korlym |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hannah Mainstain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.